Evidence map›Paper›PMID 35957887›Full record

ArticleFrontiers in oncology2022

Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling

Yiming Li, Cong Xu, Bo Sun, Fangjing Zhong, Momo Cao, Lianyue Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yiming LiLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Cong XuLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Bo SunLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Fangjing ZhongLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Momo CaoLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Lianyue YangLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumors worldwide due to the high incidence rate of metastasis and recurrence. Semaphorin 3d (Sema3d) has been shown to play a critical role in vascular development during early embryogenesis and several forms of cancer progression

Indexed as

cancer progressionEMThepatocellular carcinomaPi3k/Akt signalingprognosisSema3dsemaphorin 3d

Identifiers

PMID35957887
PMCPMC9358705
OpenAlexW4287306959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.